Saturday 17 October 2026
Export IMMX’s income statement to Excel — free account
Immix Biopharma, Inc.
IMMX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 18.2% and free cash flow fell 116.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
7.98
0.70
−8.06%
Follow IMMX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
10.01 | 2.33 | 5.32 | 11.70 | 90.03 | 0.10 | 0.20 | — |
Net Debt/EBITDA |
3.39 | 0.78 | 1.09 | 1.64 | 13.66 | (8.10) | 0.87 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 750.56% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.86) | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.81 | 0.68 | 0.74 | 0.90 | 0.07 | 0.35 | 0.81 | — |
Capex/Depreciation |
(2.01) | (10.21) | (9.47) | 0.00 | (0.01) | 0.00 | (6.64) | — |
Interest Coverage |
— | — | — | (16,437.80) | (7.52) | (4.45) | (7.66) | — |
| (55.00%) | (146.76%) | (105.07%) | (52.84%) | (367.80%) | 27.41% | 0.00% | — | |
| (46.07%) | (100.82%) | (88.57%) | (49.73%) | (260.35%) | (154.86%) | (206.34%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (244.50%) | 0.00% | 0.00% | — |
Return on Tangible Assets |
(31.44%) | (163.11%) | (95.72%) | (60.39%) | (135.54%) | 24.27% | 26.68% | — |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
Free Cash Flow per Share |
(0.75) | (0.56) | (0.66) | (0.53) | (0.43) | (0.12) | (0.24) | — |
Cash per Share |
3.05 | 0.63 | 1.01 | 0.97 | 4.80 | 0.12 | 0.22 | — |
Shareholders Equity per Share |
2.85 | 0.47 | 0.93 | 0.95 | 4.90 | (1.40) | (1.08) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
2.85 | 0.47 | 0.93 | 0.95 | 4.90 | (1.40) | (1.08) | — |
Free Cash Flow |
(24.66) | (15.77) | (11.42) | (7.41) | (1.59) | (0.40) | (0.80) | — |
Working Capital |
91.13 | 11.51 | 16.07 | 13.62 | 17.98 | (4.74) | (3.66) | — |
Capital Expenditures |
(0.73) | (1.18) | (0.05) | — | 0.00 | — | (0.01) | — |
Net Current Asset Value |
90.19 | 10.50 | 16.07 | 13.15 | 17.98 | (4.74) | (3.66) | — |
| Other line items | ||||||||
Quick Ratio |
9.93 | 2.26 | 5.02 | 10.75 | 87.48 | 0.10 | 0.20 | — |
Depreciation/Fixed assets |
0.14 | 0.07 | 0.11 | 0.58 | 10.63 | 0.31 | 0.11 | — |
Cash ROIC |
(12.70%) | (50.99%) | (33.88%) | (27.85%) | (4.46%) | 139.79% | 27.38% | — |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.73) | (0.52) | (0.66) | (0.53) | (0.43) | (0.12) | (0.23) | — |
Capex per Share |
(0.02) | (0.04) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
— | 1.57 | 0.71 | 0.14 | 0.08 | 0.15 | — | — |
Average Payables |
9.30 | 6.17 | 2.50 | 0.71 | 0.20 | 0.25 | — | — |
Average Assets |
63.89 | 21.44 | 17.42 | 16.55 | 9.37 | 0.74 | 0.47 | — |
Average Common Equity |
53.52 | 14.73 | 14.68 | 15.57 | 6.63 | (4.19) | — | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | 0.00 | — | 0.00 | — |
Columns are period end dates